Subversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice by Costa, Vivian V. et al.
1 3
Med Microbiol Immunol (2014) 203:231–250
DOI 10.1007/s00430-014-0334-5
OrIgInal InvestIgatIOn
Subversion of early innate antiviral responses 
during antibody‑dependent enhancement of Dengue virus 
infection induces severe disease in immunocompetent mice
Vivian V. Costa · Caio T. Fagundes · Deborah F. Valadão · Thiago V. Ávila · Daniel Cisalpino · Rebeca F. Rocha · 
Lucas S. Ribeiro · Fernando R. Ascenção · Lucas M. Kangussu · Celso M. Q. Junior · Ruiz G. Astigarraga · 
Frederico L. Gouveia · Tarcília A. Silva · Daniela Bonaventura · Divaldo de Almeida Sampaio · 
Ana Cristina L. Leite · Mauro M. Teixeira · Danielle G. Souza 
received: 22 October 2013 / accepted: 10 March 2014 / Published online: 11 april 2014 
© springer-verlag Berlin Heidelberg 2014
cells play a pivotal role in host responses against primary 
Denv infection in mice. after infection, μMt−/− mice 
showed increased viral loads followed by severe disease 
manifestation characterized by intense thrombocytopenia, 
hemoconcentration, cytokine production and massive liver 
damage that culminated in death. In addition, we show that 
poly and monoclonal anti-Denv-specific antibodies can suf-
ficiently increase viral replication through a suppression of 
early innate antiviral responses and enhance disease mani-
festation, so that a mostly non-lethal illness becomes a fatal 
disease resembling human DHF/Dss. Finally, treatment 
with intravenous immunoglobulin containing anti-Denv 
antibodies confirmed the potential enhancing capacity of 
Abstract Dengue is a mosquito-borne disease caused by 
one of four serotypes of Dengue virus (Denv-1–4). epi-
demiologic and observational studies demonstrate that the 
majority of severe dengue cases, dengue hemorrhagic fever 
and dengue shock syndrome (DHF/Dss), occurs predomi-
nantly in either individuals with cross-reactive immunity fol-
lowing a secondary heterologous infection or in infants with 
primary Denv infections born from dengue-immune moth-
ers, suggesting that B-cell-mediated and antibody responses 
impact on disease evolution. We demonstrate here that B 
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subneutralizing antibodies to mediate virus infection and 
replication and induce severe disease manifestation of 
Denv-infected mice. thus, our results show that humoral 
responses unleashed during Denv infections can exert pro-
tective or pathological outcomes and provide insight into the 
pathogenesis of this important human pathogen.
Keywords Dengue virus · antibody-dependent 
enhancement · DHF/Dss · type I interferons · Humoral 
response against Denv
Introduction
Dengue is an important emerging infectious disease, con-
sisting in a major public health concern. It is defined as an 
acute systemic viral infection transmitted to humans by 
Aedes mosquitoes, with a wide spectrum of clinical pres-
entations, varying from an asymptomatic or a self-limited 
illness, called dengue fever (DF), to the potentially lethal 
forms, dengue hemorrhagic fever and dengue shock syn-
drome (DHF/Dss) [1–3]. Bhatt and colleagues showed 
using updated cartographic approaches that there are 
approximately 390 million dengue infectious cases per year 
around the world, of which 96 million manifest some level 
of disease severity [4]. these numbers are even higher that 
those related previously, which suggest the occurrence of 
230 million human infections annually, of which 500,000 
are severe and 25,000 are fatal, across approximately 
100 endemic countries [3, 5, 6]. recently, a new den-
gue serotype, Denv-5, was discovered and characterized 
from samples collected during an outbreak in Malaysia’s 
sarawak state in 2007 [7]. this discovery brings even more 
challenges in the search for new targeted therapies and vac-
cines against this important human disease.
the pathogenesis of Denv infection remains poorly 
understood and involves a complex interplay between viral 
and host factors [1, 2, 8]. severe forms of disease can be 
seen during primary infections [9, 10]; however, epide-
miological and observational studies demonstrate that the 
majority of DHF/Dss cases occur predominantly in either 
individuals with secondary heterologous Denv infec-
tions or in infants born from Denv-immune mothers 
[5, 11–14]. While the exact mechanism of this phenom-
enon remains to be fully elucidated, several hypotheses 
have been raised to explain the reason for the exacerbated 
pathology found in these patients. the antibody-dependent 
enhancement of infection (aDe) theory postulates that 
after an initial period of cross-reactive protection, antibod-
ies from the first infection remain cross-reactive with other 
Denv serotypes, but have waned to subneutralizing or 
non-neutralizing levels. these non-neutralizing antibodies 
could then lead to viral internalization via the Fc portion 
of immunoglobulin g receptors (Fcγrs) and increase virus 
replication into phagocytic cells, in which is accompanied 
by massive release of soluble factors that could account for 
the increased vascular permeability and hemostatic disor-
der found in severe cases [2, 15, 16].
Interestingly, it has been demonstrated that aDe does not 
only facilitate the process of viral entry into monocytes and 
macrophages but can also modify innate and adaptive intra-
cellular antiviral mechanisms, through suppression of intra-
cellular antiviral immune responses, a phenomenon defined 
as “intrinsic aDe” (iaDe) [17]. these phenomena suggest 
that the elevated intracellular Denv production is a result 
of idiosyncratic Fc-receptor signaling. Denv immunocom-
plexes activate suppressive antiviral pathways, and the final 
outcome is a marked decrease in the production of type I 
IFns as well as the interferon-activated antiviral molecules 
(e.g., Isgs). Concomitantly, there is upregulation of anti-
inflammatory mediators, including the cytokine Il-10 [18, 
19]. similar responses have been observed in samples of 
DHF patients as compared to DF or dengue-like syndrome 
individuals [19, 20]. Overall, these events contribute to the 
elevated intracellular production of the virus.
a distinct but complementary theory of immunopathol-
ogy involves reactivation of cross-reactive memory B and t 
cells specific for the previous rather than the current Denv 
infection, resulting in delayed viral clearance and/or mas-
sive production of effectors mediators, a so-called cytokine 
storm [21, 22]. While human t-cell responses during acute 
Denv infections have been largely studied [16, 23–26], 
much less is known about the B cell and antibody responses 
to Dengue viruses infections. early studies of Boonpuck-
navig et al. [27] have demonstrated that B lymphocytes are 
increased during the acute phase of illness after a second-
ary dengue infection. another study has also found that 
DHF patients had significantly higher CD19+ B cells than 
dengue-like syndrome patients on the day of defervescence 
and 1 day after defervescence [28]. Most recently, studies 
have focused on virus-specific plasmablast responses after 
primary and secondary Denv infections. these studies 
demonstrate that rapid and massive virus-specific plasma-
blast responses were found in patients with acute Denv 
infection, especially in individuals manifesting DHF [29, 
30]. In experimental settings, B-cell responses were shown 
to be unnecessary for the control of primary Denv infec-
tion in ag129 mice [31]. However, protective cross-reac-
tive antibodies secreted by both long-lived plasma cells 
and memory B cells and both cross-reactive B and t cells 
were shown to provide protection against a secondary het-
erotypic Denv infection [32]. From the later findings, it 
seems that B cells play negligible roles in host protection 
to primary Denv infection, but may be involved in protec-
tion or disease evolution during secondary infections. How-
ever, studies are still needed to pinpoint the circumstances 
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involved in the protective or disease-enhancing activities of 
B cells and their products during this important infectious 
disease.
In the present study, we first decided to investigate 
the role played by B cells and antibodies during primary 
and secondary Dengue virus infection in mice. We con-
ducted experiments in mice infected with adapted strains 
of Denv-2 and Denv-3 that were previously shown to 
induce in immunocompetent mice a disease that resembles 
the severe dengue manifestations found in humans [33–35]. 
We demonstrate that, although B cells are pivotal for host 
resistance to primary Denv infection, passive transfer of 
anti-Denv-immune serum or subneutralizing monoclonal 
antibodies leads to the enhancement of Denv infection 
and replication as well as the occurrence of severe disease 
manifestations in mice. In addition, we show that these 
disease-enhancing activities were dependent on Fcγrs acti-
vation and consequent suppression of early innate immune 
antiviral responses in host-infected tissues. Finally, we 
demonstrate the potential deleterious effects of IvIg dur-
ing the course of Denv infection, once administration 
of IvIg containing anti-Denv antibodies to primarily 
infected mice led to increased lethality rates and to worsen-
ing of clinical signs of disease due to enhancement of virus 
replication.
Materials and methods
ethics statement
this study was carried out in strict accordance with the 
Brazilian government’s ethical and animal experiments 
regulations (law 11794/2008). the experimental protocol 
was approved by the Committee on the ethics of animal 
experiments of the Universidade Federal de Minas ger-
ais (Cetea/UFMg, Permit Protocol number 113/09). 
all surgeries were performed under ketamine/xylazine 
anesthesia, and all efforts were made to minimize animal 
suffering.
animals
B-cell-deficient mice (congenic μMt mice, strain B6-Igh6-
6tm1Cgn) were kindly provided by Dr. thiago Matar Cunha 
and Dr. João B. Calixto (FMrP-UsP, Brazil), and mice 
with null mutations for the IFnα/β receptors (a129−/− 
mice) were kindly given by Dr. adriana aballen (UFMg, 
Brazil). Wild-type controls on the C57Bl/6J (Wt) genetic 
background (back-crossed at least 10 times) were pro-
vided by Centro de Bioterismo—CeBIO, UFMg, BH, 
Brazil, and 129/sv/ev (Wt129) were kindly given by 
Dr. adriana aballen (UFMg, Brazil). all mice were bred 
and maintained at the gnotobiology and Immunology lab-
oratory of Instituto de Ciências Biológicas (ICB–UFMg). 
For experiments, 7–10-week-old mice were kept under spe-
cific pathogen-free conditions, in filtered cages with auto-
claved food and water available ad libitum.
Cell lines, monoclonal antibodies and viruses
vero cells were cultured in rPMI 1640 medium (Cul-
tilab) supplemented with 5 % inactivated fetal bovine 
serum (Cultilab). the hybridoma of mab 4g2 was pur-
chased from atCC, grown in serum-free medium (Cul-
tilab) and purified using the method of ammonium sul-
fate precipitation, followed by phosphate-buffered saline 
(PBs) dialysis and protein-a/g affinity chromatography 
as described in [36]. as control, a mouse Igg2a isotype 
control mab from acris gmbh, germany, was used. the 
hybridoma of mab clone 2.4g2 from atCC was pur-
chased from the rio de Janeiro cell Bank, grown in serum-
free medium (Cultilab) and purified as described previ-
ously. For in vivo experiments, Denv-2 and Denv-3 
strains previously adapted to mice [34, 35], respectively, 
were propagated in vero cells, and the supernatants of 
infected cells were harvested, filtered, tittered by plaque 
assay in vero cells and stored at −70 °C until use. all in 
vivo studies with the infectious viruses were performed 
in a Bsl-2 facility of the laboratório de Interação 
Microrganismo-Hospedeiro—ICB–UFMg.
experimental procedure
Infection of mice
For primary infection experiments, the virus stocks or 
mock control were diluted in endotoxin-free PBs (3.2 mM 
na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM naCl) 
and the virus inoculum “sublethal” or “lethal” of the 
adapted Denv-2 or Denv-3 (100 or 1000PFU), depend-
ing of the experiment, were injected via i.p route. as an 
additional control in some experiments, the virus was heat-
inactivated (56 °C, 1 h) before inoculation into mice. the 
results were pooled with the nI (non-infected) group just 
for easing representation of the data.
Generation of α‑DENV‑3 serum
six- to eight-week-old C57Bl/6 mice were inoculated with 
100 PFU of the adapted Denv-3 i.p. Pre-infection serum 
was collected on day zero before the infection of mice. 
Blood was obtained by tail vein bleeding every 7 days until 
day 63 post-Denv-3 inoculation. serum was separated 
from whole blood by centrifugation, heat-inactivated and 
frozen at −80 °C until use.
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Enhancement of Dengue virus infection and FcRs blockade 
in vivo
Mice were injected intraperitoneally with mabs (4g2, 15 
or 400 μg per treatment) or with the anti-Denv-3 sera 
(obtained at 49 day post-infection) in a total volume of 
200 μl on days −1, +1 and +3 after Dengue virus inocu-
lation and then infected 24 h later with a sublethal inocu-
lum of the Denv-2 or Denv-3 by i.p injection in a total 
volume of 100 μl. Igg2a mab was used as an isotype con-
trol of the anti-dengue 4g2 mab, and the Fc-blocker mab, 
clone 2.4g2 from atCC, at dose of 500 μg per/mouse 
given daily was used in some experiments.
IvIg therapy administration to mice
Mice were administered with different doses (30, 100 or 
300 mg/kg) of the 5 % IvIg solution from pooled donors 
from an endemic area for Dengue virus circulation pro-
duced by HeMOPe, recife, Brazil. the administration 
via i.v route in a final volume of 200 μl per mouse per 
treatment occurred on days −1, +1 and +3 after adapted 
Denv-3 inoculation to mice.
titration of virus by plaque assay
Mice were assayed for viral titers in blood, spleen and liver. 
Blood samples (50 μl) were collected in heparinized tubes, 
diluted in 450 μl of endotoxin-free PBs (3.2 mM na2HPO4, 
0.5 mM KH2PO4, 1.3 mM KCl, 135 mM naCl) and stored at 
−70 °C. For virus recovery from spleen and liver, the organs 
were collected aseptically in different time points and stored 
at −70 °C until assayed for Denv-2 or Denv-3 presence. 
tissue samples were weighed grounded using a pestle and 
mortar and prepared as 10 % (w/v) homogenates in rMPI 
1640 medium without fetal bovine serum (FBs). viral load in 
supernatants of tissue homogenates and blood samples were 
assessed by direct plaque assay using vero cells as described 
in [35]. results were measured as plaque-forming units (PFU) 
per gram of tissue weight or per ml of blood. the limit of 
detection of the assay was 100 PFU/g of tissue or per ml.
Plaque reduction neutralization test in vero cells
Prnt assays were performed in duplicate based on the origi-
nal protocol described by [37]. Briefly, complement was inac-
tivated by incubating serum in a 56 °C water bath for 30 min; 
then, 5 serial twofold dilutions of serum were prepared, 
starting at 1:20, in rPMI medium (Cultilab) with 5 % fetal 
bovine serum (FBs; Cultilab) and 100U penicillin/100 μg 
streptomycin (P/s; Invitrogen). Working stocks of virus were 
prepared that yielded 15–30 plaques/well in a 24-well tissue 
culture plate. viruses used for Prnt tests were the adapted 
Denv-2 and Denv-3 [34, 35], respectively. sixty microlit-
ers of each serum dilution was combined with 60 μl of virus 
and incubated for 90 min at 37 °C with 5 % CO2. after incu-
bation, 100 μl of the virus–serum mixture was transferred 
to 80 % confluent vero cells and processed as in a standard 
plaque assay. Fifty percent neutralization titer (Prnt50) val-
ues was determined as the highest serum dilution capable of 
neutralizing 50 % virus infection, as detected by the inhibi-
tion of plaque formation in cell cultures.
evaluation of blood parameters
Blood was obtained from the cava vein in heparin-contain-
ing syringes at the indicated time points under ketamine 
and xylazine anesthesia (150 mg/Kg and 10 mg/Kg, respec-
tively). the final concentration of heparin was 50 U/ml. 
serum was obtained from tail vein bleed. Platelets were 
counted in a neubauer chamber. Briefly, 10 μl of solu-
tion (blood and 1 % p/v ammonium oxalate in a dilution of 
1:100) was placed in the chamber, and platelets were visu-
alized in a nikon XP-1000 microscope, magnification of 
400×, using phase-contrast. results are presented as num-
ber of platelets per μl of blood. For the determination of the 
hematocrit, a sample of blood was collected into heparin-
ized capillary tubes (Perfecta) and centrifuged for 10 min in 
a hematocrit centrifuge (Fanem, são Paulo, Brazil).
anti-dengue IgM and Igg quantification
antibody quantification in serum from Denv-3-infected 
mice was performed by an indirect elIsa assay as adapted 
from [38]. Briefly, the same adapted Denv-3 used in infec-
tions was Uv-inactivated (60’) and diluted in 0.01 M carbon-
ate buffer (pH 9.6) in a concentration of 1 × 106 PFU per 
well of microtiter plates and incubated overnight. Plates were 
washed three times and blocked with bovine serum albumin 
1 % for 2 h and subsequently washed. then, four dilutions of 
each serum sample from 1:50 to 1:6,250 were plated in dupli-
cates and incubated for 3 h. after another wash step, plates 
were incubated for 2 h with peroxidase-conjugated anti-
mouse Igg or IgM (southern Biotech). toward, ortho-phe-
nylenediamine was used as a substrate, and the reaction was 
stopped with 1 M sulfuric acid. the absorbance was meas-
ured at 492 nm. samples of Denv-3-infected mice were con-
sidered positive in the first dilution in which mock samples 
were negative and were expressed as optical densities (O.D.).
Measurement of cytokines/chemokine concentrations
the concentration of cytokines tnF-α, IFn-γ in serum or 
Il-12p40, Il-10 and IFn-γ in spleen samples was meas-
ured using commercially available antibodies and accord-
ing to the procedures supplied by the manufacturer (r&D 
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systems, Minneapolis). results are expressed as pg/ml 
or pg/100 mg of tissue. the detection limit of the elIsa 
assays was in the range of 4–8 pg/ml.
alt transaminase activity
the activity of the transaminase alanine aminotransferase 
(alt) was measured in individual serum samples, using a 
commercially colorimetric available kit (Bioclin, Quibasa, 
Belo Horizonte, Brazil). results are expressed as the mean ± 
seM of transaminase concentration in U/dl of plasma.
evaluation of changes in vascular permeability
the extravasation of evans blue dye into the tissue was used 
as an index of increased vascular permeability, as previously 
described in [39]. Briefly, evans blue (20 mg kg−1) was 
administered i.v. (1 ml kg−1) via an eye vein 30 min prior to 
mice killing. the right ventricle was flushed with 10 ml of 
PBs to wash the intravascular evans blue in the lungs. after 
that, one lobe of liver and the left lung were cut and allowed 
to dry in a Petri dish for 24 h at 37 °C. the dry weight of the 
tissue was calculated and evans blue extracted using 1 ml of 
formamide (24 h at room temperature). the amount of evans 
blue in the tissue was obtained by comparing the extracted 
absorbance with that of a standard evans blue curve read at 
620 nm in an elIsa plate reader. results are presented as 
the amount of evans blue per 100 mg of tissue.
Hemodynamic measurements
all mice were habituated to the blood pressure measure-
ment device for 7 days. sBP was determined with tail-
cuff plethysmography method in unanesthetized mice, 
as previously described in [40]. all data are expressed as 
mean ± seM. Changes in sBP from baseline are expressed 
as absolute values as well as areas under the BP curves.
real-time PCr
For the evaluation of IFn-α2, IFnα-4 and Isg15 mrna 
expression, spleens were removed 4 and 7 days after Denv-3 
inoculation into mice. total rna was isolated from tis-
sues using a QIagen rneasy rna isolation kit. the rna 
obtained was resuspended in nuclease-free water (gIBCO) 
and stocked at −70 °C until use. real-time rt–PCr was 
performed on a applied Biosystems 7500 sequence-detection 
system (applied Biosystems) using sYBr green PCr Mas-
ter Mix (applied Biosystems) after a reverse transcription 
reaction of 2 μg of total rna by using M-Mlv reverse tran-
scriptase (Promega) and 50 μM of Oligo dt(15) (Promega). 
the relative level of gene expression was determined by 
the comparative threshold cycle method as described by the 
manufacturer, whereby data for each sample were normalized 
by 18s ribosomal rna and expressed as a fold change com-
pared with non-infected controls. the following primer pairs 
were used: 18S ribosomal RNA, 5′-CgttCCaCCaaCtaa 
gaaCg-3′ (forward) and 5′-CtCaaCaCgggaaaCCtC 
aC-3′ (reverse); and IFNα2 5′-ggaCaggCaggaCtttg 
gatt-3′ (forward) 5′-gCCttCtggatCtgCtggtaa 3′ 
IFNα4 5′-CCaCagCCCagagagtgaCCagC-3′ (for-
ward) 5′-aggCCCtCttgttCCCgaggtta-3′ (reverse) 
ISG15 5′-CtgCagCaatggCCtgggaCCt-3′ (forward) 
5′-agtttggtgggCCaggCgCt-3′.
Histopathological and immunohistochemistry analysis
liver samples from adult euthanized mice were obtained at 
the indicated time points. afterward, they were immediately 
fixed in 10 % buffered formalin for 24 h and embedded in 
paraffin. tissue sections (4 μm thicknesses) were stained 
with hematoxylin and eosin (H&e) and evaluated under a 
microscope axioskop 40 (Carl Zeiss, göttingen, germany) 
adapted to a digital camera (Powershot a620, Canon, 
tokyo, Japan). Histopathology score was performed accord-
ing to [35] evaluating hepatocyte swelling, degeneration, 
necrosis and hemorrhage, added to a five-point score (0, 
absent; 1, minimal; 2, slight; 3, moderate; 4, marked; and 5, 
severe) in each analysis. For easy interpretation, the overall 
score was taken into account and all the parameters total-
ized 20 points. a total of two sections for each animal were 
examined, and results were plotted as the media of damage 
values in each mouse. Immunohistochemistry analysis for 
detection and quantification of Denv-3-infected cells in 
liver was also performed as previously described in [35].
statistical analysis
results are shown as mean ± seM percent inhibition was 
calculated by subtracting the background values obtained 
in non-infected animals. Differences were compared using 
analysis of variance (anOva) followed by student–new-
man–Keuls post hoc analysis. Differences between lethal-
ity curves were calculated using log-rank test (graph Prism 
software 4.0). Changes in sBP from baseline are expressed 
as absolute values as well as areas under the BP curves. 
results with a P < 0.05 were considered significant.
Results
B cells are necessary for host resistance to primary Dengue 
virus infection
Humoral immune responses are thought to play a major 
role during Denv-induced disease in humans [30]. to 
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investigate in vivo the role played by B cells during Denv 
infection, wild-type (Wt) and B-cell-deficient (μMt−/−) 
mice were inoculated with 100 PFU of adapted Denv-3 i.p 
and mortality rates and disease parameters on day 7 after 
Denv inoculation (peak of disease) were evaluated. after 
infection, about 80 % of μMt−/− mice were dead at day 12 
of infection, while only 20 % of Wt mice had succumbed 
to infection after 21 days of inoculation of Denv-3 
(Fig. 1a). the earlier lethality of μMt−/− mice was asso-
ciated with increased Denv-3 replication in the spleen 
(Wt: 3.3 × 107 PFU/g (n = 5); μMt−/−: 2 × 108 PFU/g of 
spleen (n = 7), P = 0.01) and elevated viremia as assessed 
on day 7 after virus inoculation (Fig. 1b). Moreover, there 
was enhancement of ns3+ staining of hepatocytes in the 
liver of infected μMt−/− mice when compared with Wt 
(Fig. 1c). In addition to the increased lethality rates and 
to the enhanced viral replication, μMt−/− mice pre-
sented more severe manifestation of disease after infection 
(Fig. 1d–g and s1). after Denv-3 inoculation, Wt mice 
presented only mild disease manifestation as demonstrated 
by slight drop in platelets numbers (Fig. 1d), absence of 
hemoconcentration (Fig. 1e), no increase in tnF-α lev-
els in serum (Fig. 1f) and only a slight increase in alt 
transaminase levels in serum (Fig. 1g) when compared 
to non-infected (nI) mice. However, Denv-inoculated 
μMt−/− mice had greater thrombocytopenia (Fig. 1d), 
increased hematocrit levels, a marker of hemoconcentra-
tion (Fig. 1e) and elevated levels of the proinflammatory 
cytokine tnF-α in the serum (Fig. 1f). levels of IFn-
γ were elevated to a similar extent in serum of infected 
μMt−/− and Wt mice (nI: nD; Wt: 1.851.8 ± 493.2; 
μMt−/−: 2.048.7 ± 819.3), suggesting that the enhanced 
Denv replication in μMt−/− mice was not due to impair-
ment of the production of this mediator. Finally, infection 
of μMt−/− mice resulted in significant increase in serum 
levels of alt transaminase at day 7 after virus inoculation 
Fig. 1  B-cell-deficient (μMt−/−) mice are more susceptible to pri-
mary Dengue virus infection. a Wt and μMt−/− mice (n = 8 mice 
per group) were inoculated with 100PFU of Denv-3 (i.p), and 
lethality rates were evaluated every 12 h during 21 days. results are 
expressed as % of survival. In b–g, Wt (n = 5) and μMt−/− mice 
(n = 7) were inoculated with 100PFU of Denv-3 (i.p), and 7 days 
after infection, mice were culled and blood and tissue collected for 
the following analysis: b viral loads recovered from blood by plaque 
assay in vero cells. results are shown as the log of PFU per ml of 
blood. c Quantification of ns3-positive hepatocytes in the liver of 
Wt and μMt−/− mice. liver was collected, formalin-fixed and pro-
cessed into paraffin sections. serial sections from each tissue were 
stained with anti-Dv ns3 antibody e1D8 (ns3) or an isotype con-
trol mouse Igg2a, and multiple sections of each tissue type were 
thoroughly examined for staining. Positive staining for ns3 is brown, 
while hematoxylin counterstain is blue. d number of platelets, shown 
as platelets × 103/μl of blood. e Hematocrit, shown as % volume 
occupied by red blood cells. f Concentrations of tnF-α in serum, 
quantified by elIsa. results are shown as pg per ml (serum). g 
alt activity determination in plasma of control and Denv-3-in-
fected mice is shown as U/dl of plasma. all results are expressed as 
mean ± seM (except for B, expressed as median) and are representa-
tive of at least two experiments. *P < 0.05 when compared to control 
uninfected mice. #P < 0.05 when compared to Wt-infected mice. NI 
non-infected, dpi days post-infection (color figure online)
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(Fig. 1g), an indicative of liver damage. to confirm this, we 
performed histopathological analysis in the liver of Wt and 
μMt−/− mice after Denv-3 inoculation, and the results 
revealed an elevated histopathological score in μMt−/− 
mice in comparison with the Wt-infected controls (Figure 
s1). thus, the data depicted here demonstrate a protective 
role of B cells during primary Denv infection.
subneutralizing levels of anti-Denv antibodies 
enhance disease severity during Dengue virus infection 
of immunocompetent mice
We have demonstrated that B cells are necessary for host 
resistance against primary Dengue virus infection; how-
ever, it has been shown that people experiencing a second-
ary heterologous Denv infection have a much greater 
risk of developing a more severe disease manifestation 
(DHF/Dss), indicating that preexisting immunity could 
exacerbate disease [41]. thus, B-cell activation and anti-
body production can exert a dual role in Denv patho-
genesis, with potential to benefit or harm the host [11]. In 
order to evaluate whether antibodies would be involved in 
the protective role played by B cells during primary Denv 
infection, we have conducted experiments in mice injected 
with anti-Denv-immune serum. to this end, we have first 
performed a longitudinal analysis of the antibody response 
of mice primarily inoculated with Denv-3 starting on 
day 0 until day 63 after virus inoculation (Fig. 2a). Wt 
mice (n = 6) were inoculated with a sublethal inoculum 
of Denv-3 (100 PFU) and bleeding was performed every 
7 days after Denv-3 infection until day 63 post-Denv-3 
inoculation. Our data demonstrated an increased Denv-
specific IgM response at days 14 and 21 of infection. after 
day 28, the levels of IgM returned to basal values as found 
in day 0 of infection. Further, Igg responses raised on day 
14 after Denv-3 inoculation and remained elevated until 
the last day evaluated (day 63 after Dengue virus inocu-
lation) (Fig. 2a). these data demonstrated that Wt mice 
inoculated with Denv-3 were capable of mounting a 
specific-α-Denv IgM and Igg responses at the course of 
Denv infection.
to investigate the role of these antibodies in the context 
of Denv infection, Wt mice were passively transferred 
with 200μl of the Denv-3-immune serum (collected at 
day 49 of infection) at days −1, +1 and +3 after homolo-
gous (Denv-3) (Figure s2a) or heterologous (Denv-2) 
inoculation (Fig. 2b–h). Figure s2a and 2B shows that 
mice who received the Denv-3-immune serum and were 
challenged with either of Denv serotypes (Denv-3 or 
Denv-2, respectively) presented elevated lethality rates 
in comparison with mice that received only serum from 
naïve mice (Figure s2a and 2B) or serum from μMt−/− 
mice previously inoculated with a sublethal inoculum of 
Denv-3 (data not shown). after infection, only 25–30 % 
of the mice that had received the naïve serum (Fig. 2b 
and s2a) or serum from μMt−/− mice (data not shown) 
were dead until the day 14 of Denv-2 inoculation. How-
ever, on day 6 of infection, 75 % of the mice inoculated 
with the homologous serotype (Denv-3) (Figure s2a) 
and 100 % of the mice infected with the heterologous sero-
type (Denv-2) had succumbed to the infection (Fig. 2b). 
Of note, the remaining 25 % of mice that received the 
α-Denv-3 serum and were infected with the homologous 
serotype were protected from lethality (Figure s2a) and 
from disease manifestation (data not shown). since the 
transference of the Denv-3-immune serum was not protec-
tive from lethality of Denv-3-infected mice, we decided to 
evaluate the neutralizing capacity of this α-Denv-3 serum 
to neutralize Denv-3 or Denv-2 infections in vitro. Heat-
inactivated α-Denv-3 serum exhibited low neutralizing 
titers after a plaque reduction assay in vero cells (data not 
shown). these data suggest the presence of non-neutraliz-
ing or subneutralizing levels of α-Denv-3 and α-Denv-2 
antibodies, suggesting the occurrence of aDe after passive 
transfer of Denv-immune serum.
the hallmark of aDe-induced disease is an increase in 
systemic viral burden after infection. Hence, after Denv-2 
infection of mice previously administered with α-Denv-3 
serum, there was a remarkable increase in viral load 
in spleen (naïve serum = 2.2 × 10.6 PFU/g (n = 4) and 
α-Denv-3 serum = 6.1 × 10.7 PFU/g of spleen (n = 5) 
P = 0.01) and viremia (Fig. 2c) as assessed by plaque assay 
on the peak of disease manifestation after Denv-2 inocu-
lation. In addition, Panel 2D shows elevated numbers of 
ns3+ hepatocytes in the liver of mice that received Denv-
3-immune serum and were challenged with the Denv-2 
in comparison with mice treated with naïve serum and that 
were equally infected with 100 PFU of Denv-2 (Fig. 2d). 
Corroborating these findings, the increased lethality and 
the enhanced viral burden found in mice that received the 
α-Denv-3 serum was associated with more severe disease 
manifestation after Denv-2 challenge as demonstrated 
by the occurrence of marked thrombocytopenia (Fig. 2e), 
intense hemoconcentration (Fig. 2f), production of elevated 
levels of tnF-α (Fig. 2g) and higher levels of the alt 
transaminase in serum (Fig. 2h). In accordance with the 
elevated levels of alt, there was heightened liver damage 
in the liver sections of mice that received α-Denv-3 serum 
(Figure s2B). these results demonstrated that homolo-
gous or heterologous α-Denv serum transference, at sub-
neutralizing levels, can enhance the viral burden of mice 
inoculated with a sublethal inoculum of Denv, resulting in 
increased lethality and more severe disease manifestation.
to test whether the levels of anti-Denv neutralizing 
antibodies would directly impact on severe dengue disease 
evolution during infection, we conducted experiments with 
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commercial anti-Denv mabs, assessing whether different 
antibody doses would impact differently in disease mani-
festation. First, plaque reduction neutralizing titer assays 
(Prnt50) were performed in vero cells. Mice were admin-
istered with 15 or 400 μg of mouse anti-Denv monoclonal 
antibody clone 4g2 (Igg2a anti-envelope protein [e], pan-
flavivirus-reactive) or with an isotype control antibody with 
irrelevant specificity at the same doses. eighteen hours after 
antibody administration, mice were bled and the Prnt50 
titers of pre-infection serum samples were performed. 
results demonstrate that serum from mice that received the 
low dose of 4g2 antibody (15 μg) was unable to neutralize 
the Denv-3 infection in vitro. However, neutralizing titers 
were found in the serum of mice that were administered with 
the high dose of 4g2 antibody (400 μg) (data not shown). 
to determine, in vivo, the relationship between disease 
manifestation and the administered dose of anti-Denv anti-
body, Wt mice received the mouse monoclonal antibody 
4g2 at concentration of 15 μg/treatment or 400 μg/treatment 
daily (day −1, day +1 and day +3) after Denv-3 inocula-
tion. Control mice received an Igg2a isotype antibody of 
irrelevant specificity at similar concentrations and treat-
ment schedule. Figure 3a, b shows that mice that received 
the lower dose of 4g2 antibody and that were challenged 
with a sublethal inoculum of Denv-3 presented elevated 
viral replication as demonstrated by the presence of viremia 
7 days after Denv-3 inoculation (Fig. 3a), as well intense 
ns3+ hepatocytes staining, indicative of active virus replica-
tion (Fig. 3b, c). However, opposite results were found when 
mice received higher 4g2 doses. these mice presented rever-
sion of antibody enhancement of infection as demonstrated 
by the absence of viremia (Fig. 3a) and marked reduction in 
Fig. 2  Passive transference of Denv-3-immune serum decreases 
survival time and enhances Dengue virus replication and disease 
manifestation in Denv-2-inoculated mice. a Wt mice (n = 6) were 
inoculated with 100PFU of Denv-3 (i.p) and anti-dengue IgM and 
Igg titers of pre- and post-infection serum samples, collected on day 
zero and every 7 days until day 63, were measured by elIsa. results 
are expressed as arbitrary units. b Wt mice (n = 8 mice per group) 
were administered with naïve serum or anti-Denv-3 serum (col-
lected on day 49) and inoculated with 100PFU of Denv-2 (i.p), and 
lethality rates was evaluated every 12 h during 14 days. results are 
expressed as % of survival. In c–h, Wt mice (n = 5 per group) treated 
with naïve or anti-Denv-3 serum were inoculated with 100PFU of 
Denv-2 i.p), and seven days after infection, mice were culled and 
blood and tissue collected for the following analysis: c viral loads 
recovered from blood by plaque assay in vero cells. results are shown 
as the log of PFU per ml of blood. d Quantification of ns3-positive 
hepatocytes in the liver of Wt mice administered or not with anti-
Denv-3 serum. liver was collected, formalin-fixed and processed 
into paraffin sections. serial sections from each tissue were stained 
with anti-Dv ns3 antibody e1D8 (ns3) or an isotype control mouse 
Igg2a, and multiple sections of each tissue type were thoroughly 
examined for staining. Positive staining for ns3 is brown, while 
hematoxylin counterstain is blue. e number of platelets, shown as 
platelets × 103/μl of blood. f Hematocrit, shown as  % volume occu-
pied by red blood cells. g Concentrations of tnF-α in serum, quanti-
fied by elIsa. results are shown as pg per ml (serum). h alt activ-
ity determination in plasma of control and Denv-3-infected mice is 
shown as U/dl of plasma. all results are expressed as mean ± seM 
(except for c, expressed as median) and are representative of two 
experiments. *P < 0.05 when compared to control uninfected mice. 
#P < 0.05 when compared to Wt-infected naïve serum treated mice. 
NI non-infected, dpi days post-infection (color figure online)
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the numbers of ns3+ hepatocytes (Fig. 3b, c). as expected, 
no viremia (Fig. 3a) or significant ns3+ hepatocyte staining 
was detected in isotype-control-treated mice (15 or 400 μg) 
that received a small inoculum of the Denv-3 (Fig. 3b, c). In 
addition to enhanced viral replication, low-dose 4g2-treated 
mice presented more severe disease manifestation, as dem-
onstrated by intense thrombocytopenia (Fig. 3d), occurrence 
of hemoconcentration (Fig. 3e), elevated levels of tnF-α 
and alt in serum (Fig. 3f, g, respectively) when compared 
to low-dose isotype-control-treated mice. accordingly, low 
dose of 4g2 administration into mice led to marked liver 
injury on day 7 after Denv-3 inoculation (Figure s3). all 
these findings were strikingly reduced in mice that received 
the higher doses of 4g2 or the isotype control antibodies 
(Fig. 3d–g and s3). the present data demonstrate that anti-
Denv antibodies can worsen the disease outcome induced 
by Denv-3 infection in vivo, depending on their neutraliz-
ing circulating titers.
aDe-mediated severe disease manifestation resembles 
severe dengue disease induced by primary infection 
with higher viral inoculum in immunocompetent mice
Mice that receive subneutralizing amounts of anti-Denv 
antibodies presented higher viral burden during the course 
of infection. In order to evaluate whether enhanced viral 
loads would be the cause behind severe disease evolution, 
we conducted experiments comparing anti-Denv-treated 
mice infected with a lower Denv inoculum and mice 
infected only with a higher viral inoculum. For this, Wt 
mice were administered with 15 μg of the 4g2 monoclo-
nal antibody (mab) in the previously described schedule 
and then inoculated with 100PFU of Denv-3 i.p. this 
group of mice was compared to another two groups: one 
inoculated only with 100PFU of Denv-3 who was called 
as “sublethal” and another which received an inoculum 10 
times higher (1000PFU of Denv-3) that was designated 
Fig. 3  antibody-mediated enhancement of Dengue virus infec-
tion depends on antibody dose. Wt mice (n = 5–9) were adminis-
tered with (15 or 400 μg) of the mouse monoclonal antibody—4g2 
(Igg2a anti-envelope protein, pan-flavivirus-reactive) or with an iso-
type control antibody with irrelevant specificity followed by inocula-
tion of 100PFU of Denv-3 (i.p). seven days later, mice were culled 
and blood and tissue collected for the following analysis: a viral 
loads recovered from blood by plaque assay in vero cells. results are 
shown as the log of PFU per ml of blood. b Quantification of ns3-
positive hepatocytes in the liver of 4g2 or isotype-control-treated 
mice. liver was collected, formalin-fixed and processed into paraffin 
sections. serial sections from each tissue were stained with anti-Dv 
ns3 antibody e1D8 (ns3) or an isotype control mouse Igg2a, and 
multiple sections of each tissue type were thoroughly examined for 
staining. c representative pictures of positive staining for ns3+ cells 
are expressed in brown, while hematoxylin counterstain is blue. d 
number of platelets, shown as platelets × 103/μl of blood. e Hema-
tocrit, shown as  % volume occupied by red blood cells. f Concentra-
tions of tnF-α in serum, quantified by elIsa. results are shown as 
pg per ml (serum). g alt activity determination in plasma of control 
and Denv-3-infected mice is shown as U/dl of plasma. all results 
are expressed as mean ± seM (except for a, expressed as median) 
and are representative of two experiments. *P < 0.05 when compared 
to control uninfected mice. #P < 0.05 when compared to isotype 
control Denv-3-infected mice. **P < 0.05 when compared to 4g2 
(15 μg) Denv-3-infected mice. NI non-infected (color figure online)
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as “lethal”. as controls, isotype-treated mice were admin-
istered with the same dose and treatment schedule of an 
isotype-matched control with irrelevant specificity and then 
inoculated with 100 PFU of Denv-3. During the experi-
ments, euthanasia was performed at two time points after 
infection; day 4 and day 7. Figure 4a shows the lethality 
rates of mice that received or not the mabs treatment and 
were inoculated with Denv-3. results show that only 
25 % of the mice treated with the isotype control mab or 
those who were infected only with the sublethal inoculum 
of the Denv-3 were dead after 14 days of infection. In 
contrast, almost 90 % of mice that were inoculated with the 
high inoculum of the virus (lethal group) had succumbed 
to infection by day 8 after Denv-3 inoculation. simi-
lar results were found in the group of mice who received 
the 4g2 mabs. almost all mice were dead at day 11 after 
Denv-3 inoculation (Fig. 4a). In accordance with the the-
ory of the “antibody-dependent enhancement of infection,” 
the higher lethality rates found in the 4g2-treated group was 
associated with an early replication of the virus as shown 
by the presence of viremia in almost all mice already on 
day 4 of infection with even higher values at day 7 of infec-
tion (Fig. 4b). Interestingly, mice that received the higher 
inoculum of Denv-3 showed elevated viremia only at day 
7 of infection, suggesting the role of antibodies in mediat-
ing the enhancement of infection by increasing viral repli-
cation in early times after infection (Fig. 4b). as expected, 
mice that received the isotype control or the sublethal inoc-
ulum of the virus showed smaller viremia levels on day 7 
of infection when compared to the lethal and 4g2-treated 
groups (Fig. 4b). In accordance with the elevated viremia, 
marked virus replication was found in the liver of lethal-
Denv-3-inoculated or 4g2-treated mice groups, as 
assessed by ns3+ staining of hepatocytes (Fig. 4c). these 
data show that subneutralizing levels of anti-Denv anti-
bodies enhance viral replication to similar extents found 
Fig. 4  subneutralizing levels of anti-Denv mabs increases lethal-
ity rates and viral burden to levels similar to those of mice infected 
with a higher viral inoculum. a Wt mice (n = 8) were administered 
with 15 μg of the mouse monoclonal antibody—4g2 (Igg2a anti-
envelope protein, pan-flavivirus-reactive) or with an isotype control 
antibody with irrelevant specificity on days −1, +1 and +3 and were 
inoculated with 100PFU of Denv-3 (i.p). another two groups were 
inoculated only with the Denv-3 (100 PFU “sublethal” or 1000PFU 
“lethal”), without any antibody treatment. a lethality rates were eval-
uated every 12 h during 14 days. results are expressed as % of sur-
vival. b–d Wt mice (n = 5–9) were administered with 15 μg of the 
mouse monoclonal antibody—4g2 (Igg2a anti-envelope protein [e], 
pan-flavivirus-reactive) or with an isotype control antibody with irrel-
evant specificity on days −1, +1 and +3 and were inoculated with 
100PFU of Denv-3 (i.p). Four or seven days later, mice were culled 
and blood and tissue collected for the following analysis: b viral 
loads recovered from blood by plaque assay in vero cells. results are 
shown as the log of PFU per ml of blood. c Quantification of ns3-
positive hepatocytes in the liver of 4g2 or isotype-control-treated 
mice. liver was collected, formalin-fixed and processed into paraffin 
sections. serial sections from each tissue were stained with anti-Dv 
ns3 antibody e1D8 (ns3) or an isotype control mouse Igg2a, and 
multiple sections of each tissue type were thoroughly examined for 
staining. d representative pictures of positive staining for ns3+ cells 
are shown where ns3 signal is brown, while hematoxylin counter-
stain is blue. NI non-infected, dpi days post-infection. #P < 0.05 when 
compared to sublethal or isotype control Denv-3-infected mice 
(color figure online)
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in mice primarily infected with a higher Denv inoculum. 
next, we analyzed the disease parameters on days 4 and 7 
of infection using the same experimental design described 
before. Of note, there were no differences in any of the 
disease parameters evaluated among the several groups on 
the day 4 after Denv-3 inoculation (data not shown). On 
day 7 (peak of disease manifestation), our results show that 
mice that received only the sublethal inoculum of Denv-3 
or were treated with the isotype control mabs presented 
a slight reduction in the platelets counts (Fig. 5a); how-
ever, no alteration in the hematocrit levels was found after 
Denv-3 inoculation (Fig. 5b). Moderate plasma extrava-
sation in liver (Fig. 5c) and lungs [nI = 4.1 ± 0.9 μg 
100 mg lungs; sublethal = 7.9 ± 1.6 μg 100 mg lungs *; 
isotype control = 7.3 ± 1.3 μg 100 mg lungs *] as well 
as discrete reduction on systolic blood pressure (Fig. 5d) 
was found in these groups of Denv-3-inoculated mice, 
when compared to the nI controls. Beyond the hemato-
logical parameters, there was no increase in tnF-α lev-
els (Fig. 5e) in the serum of these mice; however, IFn-γ 
values (Fig. 5f) were significantly high when compared 
to the nI controls. Finally, discrete liver damage was 
found in sublethal or isotype control Denv-3-inoculated 
mice, as shown by moderate elevation in alt levels in 
the serum (Fig. 5g) and by the low scores found after the 
histopathological analysis of the H&e-stained sections 
in the liver (Fig. 5h, i). In sharp contrast, mice inoculated 
with the high inoculum of Denv-3 or those who received 
the 4g2 antibody followed by infection with a low inoc-
ulum of Denv-3 presented severe disease manifesta-
tion as demonstrated by the presence of markedly lower 
platelet counts (Fig. 5a), hemoconcentration (Fig. 5b), 
intense plasma extravasation in liver (Fig. 5c) and lungs 
[nI = 4.1 ± 0.9 μg/100 mg of lungs, lethal = 17 ± 2.3 μg 
100 mg of lungs and 4g2 = 13.3 ± 2.5 μg 100 mg of 
lungs] and severe reduction in the systolic blood pressure 
(Fig. 5d). In addition, tnF-α (Fig. 5e) and IFn-γ (Fig. 5f) 
cytokine levels in serum were markedly high in compari-
son with nI controls. Of note, Il-10 levels in the spleen 
of lethal-Denv-3-inoculated and 4g2-treated mice were 
also markedly elevated in comparison with nI, sublethal- 
and isotype-control-treated mice [nI = 36 ± 72; suble-
thal = 58 ± 89; lethal = 187 ± 126*#; isotype = 60 ± 85; 
4g2 = 187 ± 104*# pg/100 g of spleen], but similarly as 
saw in IFn-γ levels, equivalent high levels of Il-12p40 
were found in the spleen of all Denv-3-inoculated mice 
(data not shown). In addition, there was massive release of 
alt transaminase in the serum of lethal- or 4g2-treated 
mice (Fig. 5g), and histopathological analysis in the liver 
of these mice revealed that Wt mice inoculated with 
1000PFU of Denv-3 or those that received the 4g2 mab 
showed a higher score, demonstrating a significant degree 
of liver injury in these groups (Fig. 5h, i). therefore, 
treatment of mice with subneutralizing doses of anti-Denv 
monoclonal antibodies followed by challenge with a low 
inoculum of Denv led to an enhancement of disease mani-
festation in a similar way as found in mice that received an 
inoculum 10 times higher of the virus.
anti-dengue immunocomplexes enhance viral replication 
in vivo through Fcγr-mediated suppression of the type I 
IFn antiviral response
It has been proposed that interaction of Denv immuno-
complexes with Fcγrs in target cells (monocytes, mac-
rophages and DCs) enhances the access of virions to these 
cells and contributes to the increased titers of virus found 
in the blood of DHF/Dss patients [15]. to confirm the 
involvement of Fcγrs in mediating virus enhancement in 
our model of antibody-induced disease, we treated mice 
daily with an Fcγr-blocking antibody (clone 2.4g2) start-
ing on day -1 until day 5 post-Denv inoculation in mice in 
the presence or not of the anti-Denv (4g2) antibody. Our 
results show that mice administered only with the isotype 
control mab or the group of mice treated with the isotype 
control + Fcγr-blocking mab that were inoculated with 
a low inoculum of Denv-3 presented only a mild disease 
manifestation as demonstrated by no detection of virus in 
the blood (Fig. 6a), low replication levels of virus in the 
liver (Fig. 6b, c), occurrence of discrete thrombocytope-
nia (Fig. 6d) and absence of hemoconcentration (Fig. 6e). 
In addition, only small levels of tnF-α (Fig. 6f) and alt 
transaminase (Fig. 6g) were detected in serum of mice in 
these groups. Finally, histopathological scores in liver sec-
tion of these mice were low (Figure s4). However, as dem-
onstrated before in Figs. 4, 5 and here in Fig. 6a–g and s4, 
4g2 treatment of mice with subneutralizing doses followed 
by a low Denv-3 inoculation led to an enhancement of 
virus replication and increase in values of all the disease 
parameters assessed (Fig. 6a–g and s4). In contrast, block-
ade of Fcγrs by Fc-blocker treatment resulted in complete 
reversion of 4g2-induced aDe disease in mice (Fig. 6a–h 
and s4 [dark gray bars]). therefore, the present data show 
an essential role for Fcγrs in mediating enhanced viral 
burden and in inducing severe disease manifestation in 
Denv-infected mice that present subneutralizing levels of 
anti-Denv antibodies.
evidences suggest that the mechanism of aDe-enhanced 
Denv infection is associated with both increase in the 
number of infected cells, a phenomenon called “extrinsic 
aDe,” and a subversion of the intracellular innate immune 
host responses through suppression of a the type I IFn and 
proinflammatory cytokines production—an event denomi-
nated as “Intrinsic aDe” [17]. the next set of experiments 
was conducted to evaluate whether Fcγr activation by 
anti-Denv immunocomplexes would be associated with 
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impairment in host antiviral response. First, experiments 
conducted in mice with null mutations for the IFnα/β 
receptors (a129−/− mice) revealed the essential role of 
type I IFns in host response to primary Denv infection 
in the present model (Figure s5). after infection, while 
50 % of Wt mice had succumbed to infection until day 
12 (Figure s5a), almost 90 % of the type I-IFn-deficient 
mice were dead by day 7 of virus inoculation (Figure s5a). 
the increased lethality of a129−/− mice was associated 
with elevated virus replication in spleen already on day 5 
of infection (Figure s5B) and presence of higher viremia 
on day 7 after Denv inoculation (Figure s5C). In addi-
tion, there was no difference in thrombocytopenia between 
Wt- and a129−/−-infected mice (Figure s5D); however, 
hemoconcentration (Figure s5e), higher levels of tnF-
α (Figure s5F) and more intense alt (Figure s5g) were 
detected in the serum of these knockout mice in compari-
son with the Wt-infected controls.
next, we assessed type I IFn expression in spleen of 
mice allocated on the same experimental design of the 
one previously depicted for the Fig. 6. results show that 
there was a marked increase in mrna expression of the 
antiviral genes; IFNα2 (Fig. 7a), IFNα4 (Fig. 7b) and the 
IFn-induced ISG15 gene (Fig. 7c) in the spleen of mice 
that received the treatment with the isotype control mab 
and were inoculated with the low inoculum of virus, in 
Fig. 5  Mice that received subneutralizing levels of anti-Denv mabs 
develop a severe dengue disease resembling mice infected with a 
higher Denv inoculum. Wt mice (n = 5–9) were administered 
with 15 μg of the mouse monoclonal antibody—4g2 (Igg2a anti-
envelope protein, pan-flavivirus-reactive) or with an isotype control 
antibody with irrelevant specificity on days −1, +1 and +3 and were 
inoculated with 100PFU of Denv-3 (i.p). another two groups were 
inoculated only with the Denv-3 (100 PFU “sublethal” or 1000PFU 
“lethal”), without any antibody treatment. euthanasia was conducted 
on day 7 after Denv-3 inoculation, and the following parameters 
were evaluated: a number of platelets, shown as platelets × 103/μl 
of blood. b Hematocrit, shown as % volume occupied by red blood 
cells. c Changes in vascular permeability in the liver, shown as μg of 
evans blue per 100 mg of tissue. In d changes in systolic blood pres-
sure from baseline until day 7 after infection, expressed as Δ of blood 
pressure in mmHg. e–f Concentration of tnF-α and IFn-γ in serum, 
quantified by elIsa. results are shown as pg per ml (serum). g alt 
activity determination in plasma of control and Denv-3-infected 
mice is shown as U/dl of plasma. h liver of control and Denv-3-in-
fected mice were collected, formalin-fixed and processed into paraffin 
sections. liver sections were stained with hematoxylin and eosin, and 
histopathological scores of each mouse were performed. i represent-
ative images of each group of mice are shown (Scale Bar 400 μm). 
all results are expressed as mean ± seM and are representative at 
least two experiments. *P < 0.05 when compared to control unin-
fected mice. #P < 0.05 when compared to sublethal or isotype control 
Denv-3-infected mice. NI non-infected, dpi days post-infection, HS 
hepatocyte swelling, D degeneration, N necrosis, H hemorrhage, OS 
overall score
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both days 4 and 7 after Denv inoculation. similar results 
were found in mice that received the isotype control mab 
together with the Fc-blocker antibodies (Fig. 7a–c—black 
bars). Otherwise, in 4g2-treated mice equally infected with 
the same inoculum of Denv-3, a drastic suppression in the 
mrna expression of all these evaluated genes was found 
(Fig. 7a–c). Of note, IFNα2 suppression in 4g2-treated 
mice occurred as early as the day 4 of infection, supporting 
the higher viral replication found previously in this group of 
mice (Fig. 4b). Interestingly, the blockade of Fcγrs signal-
ing in 4g2-treated mice reversed this situation (Fig. 7a–c—
dark gray bars). In addition, elevated Il-10 production 
[nI = 36 ± 72; sublethal = 58 ± 89; lethal = 187 ± 126*#; 
isotype = 60 ± 85; 4g2 = 187 ± 104*# pg/100 g of 
spleen] was detected in the spleen of 4g2-treated mice 
in comparison with isotype controls littermates. Of 
note, blockade of Fcγrs in 4g2-treated mice reverted 
these phenotypes [nI = 36 ± 72; isotype = 60 ± 85; 
4g2 = 187 ± 104*#; isotype + 2.4g2 = not detectable; 
4g2 + 2.4g2 = 27 ± 54#]. therefore, the data depicted 
here show that type I IFn responses play an essential role 
during primary and secondary Denv infections and dur-
ing antibody-mediated enhancement of virus replication 
in mice; there is an early suppression of innate antiviral 
immune responses that results in enhanced Dengue virus 
replication and severe disease manifestation.
Passive intravenous immunoglobulin therapy (IvIg) 
containing subneutralizing titers of α-Denv antibodies 
enhances Dengue virus replication and induces severe 
disease manifestation in mice
specific therapeutic approaches for severe thrombocyto-
penia and shock syndrome during severe dengue are still 
lacking. Intravenous immunoglobulin g (IvIg) therapy is 
widely used to treat inflammatory and autoimmune diseases, 
Fig. 6  Fcγr blockade avoids aDe occurrence and dengue severe 
disease development in mice. Wt mice (n = 5–8 per group) were 
administered with 15 μg of the mouse monoclonal antibody—4g2 
(Igg2a anti-envelope protein, pan-flavivirus-reactive) or with an iso-
type control antibody with irrelevant specificity followed by inocula-
tion of 100PFU of Denv-3 (i.p). another two groups received the 
anti-Denv 4g2 mab together with the Fc-blocking antibody (clone 
2.4g2) or were administered with the isotype control mab and the 
Fc-blocker. seven days later, mice were culled and blood and tissues 
collected for the following analysis: a viral loads recovered from 
blood by plaque assay in vero cells. results are shown as the log of 
PFU per ml of blood. b Quantification of ns3-positive hepatocytes 
in the liver of mice. liver was collected, formalin-fixed and processed 
into paraffin sections. serial sections from each tissue were stained 
with anti-Dv ns3 antibody e1D8 (ns3) or an isotype control mouse 
Igg2a, and multiple sections of each tissue type were thoroughly 
examined for staining. c representative pictures of positive staining 
for ns3+ cells are shown where ns3 signal is brown, while hema-
toxylin counterstain is blue. d number of platelets, shown as plate-
lets × 103/μl of blood. e Hematocrit, shown as  % volume occupied 
by red blood cells. f Concentrations of tnF-α in serum, quantified 
by elIsa. results are shown as pg per ml (serum). g alt activ-
ity determination in plasma of control and Denv-3-infected mice is 
shown as U/dl of plasma. all results are expressed as mean ± seM 
(except for a, expressed as median) and are representative of two 
experiments. *P < 0.05 when compared to control uninfected mice. 
#P < 0.05 when compared to isotype control or isotype control aan 
2.4g2 Denv-3-infected mice. **P < 0.05 when compared to 4g2 
Denv-3-infected mice. NI non-infected, ND non-detected (color fig-
ure online)
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such as immunothrombocytopenia (ItP) [42]. However, the 
effects of IvIg therapy during Dengue virus infections are 
controversial [42–44]. In light of the previous results, we 
hypothesized that the prophylactic treatment of mice with 
human immunoglobulin (IvIg) from pooled blood from 
health donors from an endemic area for Dengue virus cir-
culation could worsen Denv-induced disease in mice due 
to the presence of subneutralizing titers of anti-Denv anti-
bodies. table 1 shows the composition of the IvIg used 
in the present study. as highlighted, anti-Denv antibod-
ies were detected by the Pan Bio qualitative anti-Denv 
elIsa in the IvIg used. In addition, plaque reduction neu-
tralization tests of the IvIg sample showed that the utilized 
preparation presented subneutralizing titers of anti-Denv 
antibodies (Prnt50 against the Denv-3 strain = 1:20). to 
verify the role of IvIg therapy during Dengue virus infec-
tion, Wt mice were administered intravenously with three 
different doses of α-Denv-containing IvIg (30, 100 and 
300 mg/kg) on days −1, +1 and +3 after Denv-3 inocula-
tion. Figure 8a shows that only 25 % of mice that received 
the vehicle solution succumbed to infection until day 14 
of Denv-3 inoculation. Interestingly, IvIg administration 
Fig. 7   anti-dengue antibodies mediate suppression of early antivi-
ral innate immune responses in spleen of mice infected with Denv-3 
through Fcgr activation. Wt mice (n = 5 per group) were admin-
istered with 15 μg of the mouse monoclonal antibody—4g2 (Igg2a 
anti-envelope protein, pan-flavivirus-reactive) or with an isotype 
control antibody with irrelevant specificity followed by inoculation 
of 100PFU of Denv-3 (i.p). another two groups received the anti-
Denv 4g2 mab together with the Fc-blocking antibody (clone 
2.4g2) or were administered with the isotype control mab and the 
Fc-blocker and were infected with 100PFU of Denv-3. Four or 
seven days later, mice were culled and spleen was collected for the 
determination of IFn-α2 (a), IFn-α4 (b) and Isg15 (c) rna expres-
sion by qPCr. results are shown as mean ± seM of fold increase 
over basal expression in naive mice. all results are representative of 
two experiments. *P < 0.05 when compared to control uninfected 
mice. #P < 0.05 when compared to isotype control or isotype control 
and 2.4g2 Denv-3-infected mice. **P < 0.05 when compared to 
4g2 Denv-3-infected mice. NI non-infected
Table 1  Characteristics and composition of the 5 % human immune 
globulin intravenous solution produced by the HeMOPe, recife, 
Brazil
Formulation: 0.3M glycine
the isolation of the human immunoglobulin g (IvIg) from a pull of 
serum donors from an endemic region for Dengue virus was made by 
the method of Cohn–Oncley. the characteristics and composition of 
the IvIg are demonstrated above
a
 Using the methodologies recommended in the european Pharmaco-
poeia, vI edition
analysisa standard values IvIg α-Denv
Protein concentration Minimum 30 mg/ml 51.1 mg/ml
Protein composition (purity) Minimum 95 % 96,80 %
pH 4.0–7.4 4.51
Quantification of aggregates <3 % 1.8 %
anti-HBs Minimum 0.5 UI/g 8.7 UI/g
Immunoglobulin concentration
 Igg – 44.4 mg/mIJ
 Iga – l.25 mg/ml
 IgM – 0.25 mg/ml
 Ige – 0.03 mg/ml
anticomplementary (CH50) <1 <1
 anti-Hlvl abs absent absent
 anti-HIv2 abs absent absent
 anti-HBsag absent absent
anti-streptococcus abs – Present
 anti-measles – Present
 anti-DengUe abs _ Present
stability at 57°/4 h Do not freeze Do not freeze
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to Denv-3-inoculated mice led to an enhancement of the 
lethality rates varying between 50 % at dose of 30 mg/kg 
and 75 % at doses of 100 or 300 mg/kg per mouse/per treat-
ment. Further analyses of disease parameters were done 
administering the dose of 100 mg/kg. In addition to elevated 
lethality rates, administration of α-Denv-containing IvIg 
led to severe disease manifestation and enhancement of 
virus replication (Fig. 8b–g). While vehicle-treated mice 
presented moderate viremia (Fig. 8b), viral load in blood 
of mice administered with α-Denv-containing IvIg was 
2log higher at the same period analyzed. In accordance, the 
presence of ns3+ hepatocytes was markedly increased in 
IvIg-treated mice in comparison with vehicle-treated ones 
(Fig. 8c). Hematological parameters were also aggravated in 
IvIg-treated mice as demonstrated by intense drop in plate-
lets numbers (Fig. 8d), occurrence of hemoconcentration 
(Fig. 8e), heightened production of the pro-inflammatory 
cytokine tnF-α (Fig. 8f) and hepatic damage (Fig. 8g and 
s6). next, we assessed the neutralizing titers of α-Denv 
antibodies in the serum of IvIg-treated mice in vitro. 
Plaque neutralization assays from serum of mice admin-
istered with 100 mg/kg of IvIg revealed non-neutraliz-
ing titers (data not shown), and these results corroborate 
the findings shown before that subneutralizing doses of 
α-Denv antibodies can enhance Dengue virus replication 
and disease manifestation in mice.
Discussion
the major findings of the present study can be summa-
rized as follows: (1) B cells play a protective role in the 
Fig. 8  Passive intravenous immunoglobulin therapy (IvIg) contain-
ing subneutralizing levels of α-Denv antibodies reduce survival 
rates, enhance Dengue virus replication and induce severe disease 
manifestation in Denv-3-inoculated mice. a Wt mice (n = 8) were 
administered with different doses of the α-Denv IvIg (30, 100 or 
300 mg/kg) or with the vehicle solution (i.v) on days −1, +1 and +3 
and were inoculated with 100PFU of Denv-3 (i.p). a lethality rates 
were evaluated every 12 h during 14 days. results are expressed as 
% of survival. b–g Wt mice (n = 8–11) were administered with the 
α-Denv IvIg (100 mg/kg) or with the vehicle solution (i.v) on days 
−1, +1 and +3 and 7 days after Denv-3 infection, mice were culled 
and blood and tissue collected for the following analysis: b viral 
loads recovered from blood, assayed by plaque assay in vero cells. 
results are shown as the log of PFU per ml of blood. c Quantifica-
tion of ns3-positive hepatocytes in the liver of 4g2 or isotype-con-
trol-treated mice. liver was collected, formalin-fixed and processed 
into paraffin sections. serial sections from each tissue were stained 
with anti-Dv ns3 antibody e1D8 (ns3) or an isotype control mouse 
Igg2a, and multiple sections of each tissue type were thoroughly 
examined for staining. representative pictures of positive staining 
for ns3+ cells are shown, where ns3 signal is brown, while hema-
toxylin counterstain is blue. d number of platelets, shown as plate-
lets × 103/μl of blood. e Hematocrit, shown as  % volume occupied 
by red blood cells. f Concentrations of tnF-α in serum, quantified 
by elIsa. results are shown as pg per ml (serum). g alt activ-
ity determination in plasma of control and Denv-3-infected mice is 
shown as U/dl of plasma. *P < 0.05 when compared to control unin-
fected mice. #P < 0.05 when compared to vehicle-treated and Denv-
3-infected mice. NI non-infected, dpi days post-infection, ND non-
detected (color figure online)
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host response to primary Dengue virus infection in mice; 
(2) subneutralizing titers of anti-dengue antibodies enhance 
Denv infection and replication, leading to severe disease 
manifestation and increased lethality rates of immunocom-
petent mice in a similar way as found in DHF patients; (3) 
enhanced Denv replication mediated by subneutraliz-
ing levels of anti-Denv antibodies involves Fcγr activa-
tion and subsequent impairment of host type I interferon 
responses and elevated production of the anti-inflammatory 
cytokine Il-10; (4) IvIg replacement therapy containing 
subneutralizing levels of anti-Denv antibodies led to more 
severe disease manifestation and increased lethality rates 
due to an enhancement of virus replication. these studies, 
therefore, indicate that B cells are pivotal for host resist-
ance to primary Dengue virus infections although humoral 
responses unleashed during secondary infections may con-
tribute to the enhancement of virus replication and severe 
disease manifestation in mice due to suppression of the 
early antiviral innate responses.
the adaptive immune response to Dengue viruses is 
thought to contribute to the resolution of infection and 
to play a major role in protection from reinfection [45]. 
Conversely, it is also believed to have a crucial role in the 
enhancement of disease severity seen in patients with DHF 
or Dss [46]. It has been previously demonstrated that there 
is early B-cell activation upon Denv infection of immuno-
competent mice, with detectable levels of anti-Denv anti-
bodies as early as 3 days post-infection. However, the same 
group showed that B-cell-deficient mice are as resistant to 
Denv-induced lethality as Wt mice [31] although viral 
replication and disease parameters were not thoroughly 
addressed due to limitations of the experimental model 
utilized. therefore, the data obtained so far have failed to 
properly define the role played by B cells during the course 
of Denv infection. Here, we have performed experiments 
in B-cell-deficient mice (μMt−/−) using Denv strains 
shown to replicate in relevant host tissues and to induce a 
severe disease that resembles most of the parameters found 
in patients with DHF/Dss when primarily inoculated 
into immunocompetent mice [33–35]. Our data clearly 
show that μMt−/−mice were more susceptible to Denv 
infection than Wt-infected controls. Denv-3-inoculated 
μMt−/− presented elevated lethality rates, and importantly, 
lethality was associated with a systemic dissemination of 
the virus as well as with enhanced disease manifestation, as 
exemplified by the presence of marked thrombocytopenia, 
hemoconcentration, elevated levels of tnF-α and alt in 
serum as well as an intense liver damage. these findings 
highlight the pivotal role played by early B-cell activa-
tion in controlling viral replication and disease evolution 
and are divergent from previous studies utilizing animal 
models of infection [31]. It is important to emphasize that 
such discrepancies may be justified by the use of different 
viral strains (serotypes/genotypes), as well as the differ-
ent experimental protocols used in these studies. thus, the 
reader should be cautious during the interpretation of such 
data. also, the higher complexity of the human immune 
system in relation to the murine one should be taken into 
account when interpreting the current findings. But the data 
presented here strongly support a protective role for B cells 
during primary Denv infection and are in accordance with 
the role played by B-cell-mediated immunity during infec-
tion by other flaviviruses [47, 48].
the mechanisms involved in B-cell-mediated protec-
tion to Denv infection are still to be defined. recently, it 
has been shown that B cells are important for proper innate 
antiviral responses by controlling macrophage mainte-
nance and production of type I IFns upon vsv infection 
[49]. also, B cells seem to play a pivotal role during innate 
responses to systemic infections. Kelly-scumpia et al. 
[49, 50] have demonstrated that during bacterial sepsis, 
type-I-IFn-mediated activation of marginal zone and fol-
licular B cells contributed to early chemokine production 
and to improved survival rates. thus, these two studies 
have identified a novel protective role for type I IFn and B 
cells during early immune responses to viral and systemic 
infections. since type I IFn responses are essential during 
Denv infection and B-cell-deficient mice were markedly 
susceptible to primary Denv infection, similar mecha-
nisms as described before could account to the severe dis-
ease manifestation observed in Denv-infected μMt−/− 
mice. However, future studies are needed to clarify these 
speculations.
In the previously cited work by Diamond and colleagues, 
it was found that μMt−/− mice developed increased viral 
burden and higher lethality rates upon Wnv infection, 
similarly to what we have found in our system during the 
course of Denv infection [47]. Importantly, they have also 
shown that passive transfer of heat-inactivated serum from 
Wt immune mice to μMt−/− mice protected them against 
morbidity and mortality induced by Wnv inoculation, sug-
gesting that antibodies are important for conferring protec-
tion to infection [47]. In order to evaluate whether antibod-
ies would confer protection also to Denv infection, we 
have conducted experiments involving passive transfer of 
Denv-immune serum to mice, but we had strikingly dif-
ferent results. Hence, the administration of anti-Denv 
serum to immunocompetent mice can sufficiently increase 
severity of disease, so that a mostly non-lethal illness 
becomes a fatal disease. similar results were found with 
the administration of subneutralizing titers of monoclonal 
anti-Denv antibodies. Of note, antibody-induced disease 
manifestation was completely reversed when higher doses 
of anti-Denv mabs were administered to mice. these 
experiments suggested the occurrence of aDe phenom-
enon in vivo.
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Findings in other experimental systems have previously 
suggested the occurrence of aDe of Denv infection in 
vivo. the first evidences came from experiments con-
ducted in non-human primates [51, 52]. In vivo enhance-
ment of Dengue virus infection in rhesus monkeys was 
detected after passive transfer of antibodies [52, 53]. How-
ever, despite the elevated viral titers detected, no signs of 
disease were apparent, which limits the study of Dengue 
virus pathogenesis in this system. recently, studies con-
ducted in ag129 mice have also brought support to this 
theory, showing the occurrence of many DHF/Dss signs of 
disease and symptoms after passive transfer of polyclonal-
immune serum or anti-Denv mabs [54, 55]. the fact that 
these studies were conducted in IFn receptor-deficient 
mice tempered further extrapolations to human situation, 
due to the essential role of IFn responses in both patho-
genesis and protection against Denv infections. Of note, 
mice in the sv129 background are much more susceptible 
to infection by dengue than the C57Bl/6 strain, which jus-
tify the difference in mortality rates found in both groups 
when infected with the same inoculums of dengue in this 
study. Our results in a immunocompetent system showed 
that after inoculation of a low inoculum of Denv-3 to mice 
treated with a low dose of the 4g2 antibody, there was 
increased viral burden together with marked thrombocyto-
penia, occurrence of hemoconcentration, increased vascular 
permeability, reduction in arterial blood pressure as well as 
elevated levels of tnF-α and hepatic transaminases in the 
serum, all parameters found in humans with DHF/Dss. In 
addition, intense liver damage was detected in anti-Denv 
mabs-treated mice. the latter findings clearly show the 
occurrence of the aDe phenomenon in immunocompetent 
settings and demonstrate that aDe may impact in both viral 
burden and disease evolution in vivo. this system utilizing 
aDe-mediated Denv infection in immunocompetent mice 
may provide an important tool to study host–virus interac-
tions during secondary Denv infection.
Of note, aDe-induced disease manifestation was com-
pletely reversed after the blockade of Fcγrs. this is in 
accordance with previous findings by other groups, show-
ing that antibody-induced disease could be prevented by 
blockade of interaction between the virus immunocom-
plexes to the Fcγrs, through the use of anti-Fcγr mabs 
or by the administration of genetically modified antibodies 
that are incapable of interacting with the Fcγrs [54, 55]. 
this Fcγr-dependent antibody-enhanced infection can also 
be reproduced in cell culture models. In fact, in addition to 
enabling viral entry into target cells, it has been suggested 
that Fcγr activation by Denv–antibodies complexes 
may interfere in cellular antiviral responses, in a mecha-
nism called intrinsic aDe (iaDe) [17, 18, 56, 57]. Hence, 
it was demonstrated that Denv–antibody complexes 
activated negative regulators of the rIg-I and MDa-5 
cascade, resulting in suppression of type I interferon pro-
duction and to impairment of the interferon-mediated anti-
viral responses. Modhiran et al. [58] have demonstrated 
in tHP-1 cells that interaction between Denv–antibody 
complexes and Fcγrs may also downregulate tlr gene 
expression and upregulate negative regulators of the nF-κB 
pathway, resulting in suppression of innate responses and 
increased viral production. Importantly, these alterations 
in gene expression were also described in cells of patients 
experiencing secondary DHF/Dss but not in DF patients 
[18, 58]. In the present study, we found that there was 
marked suppression in expression of the IFNα2, IFNα4 
and ISG15 genes in the spleen of anti-dengue mab-treated 
mice. Importantly, these effects were attenuated by block-
ade of Fcγ-receptors, suggesting the occurrence of the 
iaDe phenomenon in the current experimental settings. to 
our knowledge, this is the first demonstration of the iaDe 
phenomenon in vivo. these data also suggest that iaDe 
occurrence impacts on severe disease manifestation during 
secondary dengue infection.
another event shown to occur during iaDe involves the 
production of the suppressive cytokine Il-10. It was previ-
ously shown that after internalization of Denv–antibody 
complexes in tHP-1 cells, there is induction of high levels 
of Il-10 and expression of the regulatory molecule sOCs3, 
culminating in the inhibition of nitric oxide production and 
enhanced viral replication. Interestingly, we have found 
elevated Il-10 levels in spleen of anti-Denv mab-treated 
mice on day 7 after Denv inoculation, suggesting that this 
mechanism may take place in vivo. this finding, in concert 
with the fact that Il-10 host genetic polymorphisms influ-
ence antibody-dependent enhancement of Denv infec-
tion, suggests that this pathway may be relevant to severe 
disease manifestation during Denv infection [59, 60]. 
altogether, these findings show that there is suppression of 
early antiviral innate responses during antibody-mediated 
Denv infection, resulting in excessive virus replication 
and severe disease manifestation.
specific therapeutic options for severe thrombocyto-
penia and shock syndrome, the main causes of mortality 
during severe dengue disease, are still lacking [1, 42]. the 
aDe phenomenon is considered a major bottleneck dur-
ing the vaccine design and antibody therapeutic approaches 
development [15, 61, 62]. this seems to be the case for 
application of the IvIg therapy. this so-called intrave-
nous immunoglobulin g therapy involves the application 
of pooled immunoglobulin g (Igg) preparations from thou-
sands of donors to patients with a variety of hematological 
and immunological disorders [63]. Prophylactic and thera-
peutic efficacies of IvIg therapy have been reported during 
some Flavivirus infections, such as West nile virus (Wnv) 
and tick-borne encephalitis virus (tBev) [44, 64]. How-
ever, in the context of Dengue virus infections, trials so far 
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have not shown any significant benefit in terms of survival 
or improvement in clinical parameters of patients submit-
ted to the IvIg therapy [42, 43]. Our data clearly showed 
that replacement IvIg therapy containing subneutralizing 
titers of anti-Denv antibodies potentiated Denv infec-
tion and replication and induced severe disease manifes-
tation in Denv-infected mice, suggesting that aDe may 
impact negatively the outcome upon IvIg therapy during 
Denv infection. these data suggest that different formula-
tions of the IvIg should be developed in the case of any 
application of this therapy during the course of Denv 
infection. this assertion is supported by the finding that 
treatment with anti-D (rh0 D Igg) immune globulin (Win-
rho® sDF), a preparation highly effective in producing 
Fc-receptor blockade, resulted in increase in platelet counts 
in DHF patients [65]. therefore, proper formulations for 
IvIg preparations should be sought for application of this 
therapy to Denv-infected patients.
In conclusion, we have demonstrated that B cells play an 
essential role during protection of primary Denv infection 
in mice. However, our results also show that subneutraliz-
ing levels of anti-Denv-specific antibodies may aggravate 
the course of infection due to the enhancement of virus 
infection and replication in Fc-bearing cells through Fcγr-
mediated suppression of early antiviral innate responses. 
these data confirm the aDe phenomenon occurrence in 
vivo in mice with an intact immune system and highlight 
the great impact aDe-mediated infection exerts in severe 
dengue disease manifestation. Finally, we have demon-
strated that these events involved in aDe occurrence may 
impact negatively in replacement IvIg therapy during the 
course of Denv infection. therefore, the aDe phenome-
non represents a major constraint for utilizing IvIg therapy 
in Denv-infected patients.
Acknowledgments We thank Ilma Marçal, gilvânia Ferreira da 
silva santos and Franckcinéia assis (ICB/UFMg) for technical 
assistance. Instituto nacional de Ciência e tecnologia em Dengue 
(InCt-Dengue); PrOneX em Dengue (Ministério da saúde), Bra-
zil; Conselho nacional de Ciência de Desenvolvimento Científico e 
tecnológico (CnPq); Coordenação de aperfeiçoamento de Pessoal de 
nível superior (CaPes); Fundação de amparo à Pesquisa do estado 
de Minas gerais (FaPeMIg). vvC and CtF are supported by the 
“science without Borders” program.
Conflict of interest the authors have no conflicting financial 
interests.
References
 1. Fagundes Ct, Costa vv, Cisalpino D, souza Dg, teixeira MM 
(2011) therapeutic opportunities in dengue infection. Drug Devel 
res 72:480–500. doi:10.1002/ddr.20455
 2. Costa vv, Fagundes Ct, da gloria de souza D, teixeira 
MM (2013) Inflammatory and innate immune responses in 
dengue infection: protection versus disease induction. am J 
Pathol 182(6):1950–1961. doi:10.1016/j.ajpath.2013.02.027
 3. simmons CP, Farrar JJ, nguyen vv, Wills B (2012) Dengue. n 
engl J Med 366:1423–1432. doi:10.1056/neJMra1110265
 4. Bhatt s, gething PW, Brady OJ, Messina JP, Farlow aW, Moyes 
Cl, Drake JM, Brownstein Js, Hoen ag, sankoh O, Myers MF, 
george DB, Jaenisch t, Wint gr, simmons CP, scott tW, Farrar 
JJ, Hay sI (2013) the global distribution and burden of dengue. 
nature 496:504–507. doi:10.1038/nature12060
 5. guzman Mg, alvarez M, Halstead sB (2013) secondary infec-
tion as a risk factor for dengue hemorrhagic fever/dengue shock 
syndrome: an historical perspective and role of antibody-depend-
ent enhancement of infection. arch virol 158(7):1445–1459. 
doi:10.1007/s00705-013-1645-3
 6. Wilder-smith a, renhorn K-e, tissera H, Bakar sa, alphey l, 
Kittayapong P, lindsay steve, logan J, Hatz C, reiter P, rocklov 
J, Byass Peter, louis vr, tozan Y, Massad e, tenorio a, lag-
neau C, l’ambert g, Brooks D, Wegerdt J, gubler D (2012) Den-
guetools: innovative tools and strategies for the surveillance and 
control of dengue. glob Health action 5:17273. doi:10.3402/gha.
v5i0.17273
 7. normile D (2013) surprising new Dengue virus throws a spanner 
in disease control efforts. science 342(6157):415. doi:10.1126/
science.342.6157.415
 8. guzman Mg, Halstead sB, artsob H, Buchy P, Farrar J, gubler 
DJ, Hunsperger e, Kroeger a, Margolis H, Martinez e, nathan 
MB, Pelegrino Jl, simmons C, Yoksan s, Peeling rW (2010) 
Dengue: a continuing global threat. nat rev Microbiol 8:s7–s16. 
doi:10.1038/nrmicro2460
 9. Balmaseda a, Hammond sn, Perez l, tellez Y, saborio sI, Mer-
cado JC, Cuadra r, rocha J, Perez Ma, silva s, rocha C, Harris 
e (2006) serotype-specific differences in clinical manifestations 
of dengue. am J trop Med Hyg 74:449–456
 10. Clyde K, Kyle Jl, Harris e (2006) recent advances in deci-
phering viral and host determinants of Dengue virus replica-
tion and pathogenesis. J virol 80:11418–11431. doi:10.1128/
JvI.01257-06
 11. Wahala WM, silva aM (2011) the human antibody response 
to Dengue virus infection. viruses 3:2374–2395. doi:10.3390/
v3122374
 12. Kliks sC, nimmanitya s, nisalak a, Burke Ds (1988) evidence 
that maternal dengue antibodies are important in the development 
of dengue hemorrhagic fever in infants. am J trop Med Hyg 
38:411–419
 13. Chau tn, Quyen nt, thuy tt, tuan nM, Hoang DM, Dung 
ntP, lien lB, Quy nt, Hieu nt, Hien tt, Hung nt, Farrar 
J, simmons C (2008) Dengue in vietnamese infants–results of 
infection-enhancement assays correlate with age-related disease 
epidemiology, and cellular immune responses correlate with dis-
ease severity. J Infect Dis 198:516–524. doi:10.1086/590117
 14. Chau tn, Hieu nt, anders Kl, Wolbers M, le lien B, Hieu lt, 
Hien tt, Hung nt, Farrar J, Whitehead, simmons CP (2009) 
Dengue virus infections and maternal antibody decay in a pro-
spective birth cohort study of vietnamese infants. J Infect Dis 
200:1893–1900. doi:10.1086/648407
 15. Murphy Br, Whitehead ss (2011) Immune response to Dengue 
virus and prospects for a vaccine. annu rev Immunol 29:587–
619. doi:0.1146/annurev-immunol-031210-101315
 16. rothman al (2011) Immunity to Dengue virus: a tale of origi-
nal antigenic sin and tropical cytokine storms. nat rev Immunol 
11:532–543. doi:10.1038/nri3014
 17. Halstead sB, Mahalingam s, Marovich Ma, Ubol s, Mosser 
DM (2010) Intrinsic antibody-dependent enhancement of 
microbial infection in macrophages: disease regulation by 
immune complexes. lancet Infect Dis 10:712–722. doi:10.1016/
s1473-3099(10)70166-3
249Med Microbiol Immunol (2014) 203:231–250 
1 3
 18. Chareonsirisuthigul t, Kalayanarooj s, Ubol s (2007) Den‑
gue virus (Denv) antibody-dependent enhancement of infec-
tion upregulates the production of anti-inflammatory cytokines, 
but suppresses anti-Denv free radical and pro-inflammatory 
cytokine production, in tHP-1 cells. J gen virol 88:365–375. doi
:10.1099/vir.0.82537-0
 19. Ubol s, Phuklia W, Kalayanarooj s, Modhiran n (2010) Mecha-
nisms of immune evasion induced by a complex of Dengue virus 
and preexisting enhancing antibodies. J Infect Dis 201:923–935. 
doi:10.1086/651018
 20. Ubol s, Masrinoul P, Chaijaruwanich J, Kalayanarooj s, Char-
oensirisuthikul t, Kasisith J (2008) Differences in global gene 
expression in peripheral blood mononuclear cells indicate a sig-
nificant role of the innate responses in progression of dengue 
fever but not dengue hemorrhagic fever. J Infect Dis 197:1459–
1467. doi:10.1086/587699
 21. Mongkolsapaya J, Dejnirattisai W, Xu Xn, vasanawathana 
s, tangthawornchaikul n, Chairunsri a, sawasdivorn s, 
Duagchinda t, Dong t, rowland-Jones s, Yenchitsomanus Pt, 
McMichael a, Malasit P, screaton g (2003) Original antigenic 
sin and apoptosis in the pathogenesis of dengue hemorrhagic 
fever. nat Med 9:921–927. doi:10.1038/nm887
 22. Midgley CM, Bajwa-Joseph M, vasanawathana s, limpitikul W, 
Wills B, Flanagan a, Waiyaiya e, tran HB, Cowper ae, Choti-
yarnwong P, grimes JM, Yoksan s, Malasit P, simmons CP, 
Mongkolsapaya J, screaton gr (2011) an in-depth analysis of 
original antigenic sin in Dengue virus infection. J virol 85:410–
421. doi:10.1128/JvI.01826-10
 23. rothman al (2010) Cellular immunology of sequen-
tial Dengue virus infection and its role in disease patho-
genesis. Curr top Microbiol Immunol 338:83–98. 
doi:10.1007/978-3-642-02215-9_7
 24. Friberg H, Bashyam H, toyosaki-Maeda t, Potts Ja, greenough 
t, Kalayanarooj s, gibbons rv, nisalak a, srikiatkhachorn a, 
green s, stephens Ha, rothman al, Mathew a (2011) Cross-
reactivity and expansion of dengue-specific t cells during acute 
primary and secondary infections in humans. sci rep 1:51. 
doi:10.1038/srep00051
 25. Friberg H, Burns l, Woda M, Kalayanarooj s, endy tP, stephens 
Ha, green s, rothman al, Mathew a (2011) Memory CD8 + t 
cells from naturally acquired primary Dengue virus infection are 
highly cross-reactive. Immunol Cell Biol 89:122–129. doi:10.103
8/icb.2010.61
 26. Mangada MM, rothman al (2005) altered cytokine responses 
of dengue-specific CD4 + t cells to heterologous serotypes. J 
Immunol 175:2676–2683
 27. Boonpucknavig s, lohachitranond C, nimmanitya s (1979) the 
pattern and nature of the lymphocyte population response in den-
gue hemorrhagic fever. am J trop Med Hyg 28:885–889
 28. Jampangern W, vongthoung K, Jittmittraphap a, Worapongpai-
boon s, limkittikul K, Jampangern W, Chuansumrit a, tarunotai 
U, Chongsa-nguan M (2007) Characterization of atypical lym-
phocytes and immunophenotypes of lymphocytes in patients with 
Dengue virus infection. asian Pac J allergy Immunol 25:27–36
 29. garcia-Bates tM, Cordeiro Mt, nascimento eJ, smith aP, 
soares de Melo KM, McBurney sP, evans JD, Marques et Jr, 
Barratt-Boyes sM (2013) association between magnitude of 
the virus-specific plasmablast response and disease severity 
in dengue patients. J Immunol 190:80–87. doi:10.4049/jimmu
nol.1103350
 30. Wrammert J, Onlamoon n, akondy rs, Perng gC, Polsrila K, 
Wrammert J, Chandele a, Kwissa M, Pulendran B, Wilson PC, 
Wittawatmongkol O, Yoksan s, angkasekwinai n, Pattanapan-
yasat K, Chokephaibulkit K, ahmed r (2012) rapid and mas-
sive virus-specific plasmablast responses during acute Dengue 
virus infection in humans. J virol 86:2911–2918. doi:10.1128/
JvI.06075-11
 31. shresta s, Kyle Jl, robert Beatty P, Harris e (2004) early activa-
tion of natural killer and B cells in response to primary Dengue 
virus infection in a/J mice. virology 319:262–273
 32. Zompi s, Montoya M, Pohl MO, Balmaseda a, Harris e (2012) 
Dominant cross-reactive B cell response during secondary acute 
Dengue virus infection in humans. Plos negl trop Dis 6:e1568. 
doi:10.1371/journal.pntd.0001568
 33. atrasheuskaya a, Petzelbauer P, Fredeking tM, Ignatyev g 
(2003) anti-tnF antibody treatment reduces mortality in experi-
mental Dengue virus infection. FeMs Immunol Med Microbiol 
35:33–42. doi:10.1111/j.1574-695X.2003.tb00646.x
 34. souza Dg, Fagundes Ct, sousa lP, amaral Fa, souza rs, souza 
al, Kroon eg, sachs D, Cunha FQ, Bukin e, atrasheuskaya a, 
Ignatyev g, teixeira MM (2009) essential role of platelet-acti-
vating factor receptor in the pathogenesis of Dengue virus infec-
tion. Proc natl acad sci Usa 106:14138–14143. doi:10.1073/p
nas.0906467106
 35. Costa vv, Fagundes Ct, valadao DF, Cisalpino D, Dias aC, 
Costa vv, silveira KD, Kangussu lM, Ávila tv, Bonfim Mr, 
Bonaventura D, silva ta, sousa lP, rachid Ma, vieira lQ, 
Menezes gB, de Paula aM, atrasheuskaya a, Ignatyev g, teix-
eira MM, souza Dg (2012) a model of Denv-3 infection that 
recapitulates severe disease and highlights the importance of 
IFn-gamma in host resistance to infection. Plos negl trop Dis 
6:e1663. doi:10.1371/journal.pntd.0001663
 36. Page M, thorpe r (1998) Purification of monoclonal antibodies. 
Methods Mol Biol 80:113–119
 37. russell PK, nisalak a (1967) Dengue virus identification by the 
plaque reduction neutralization test. J Immunol 99:291–296
 38. garcia CC, russo rC, guabiraba r, Fagundes Ct, Polidoro 
rB, tavares lP, salgado aP, Cassali gD, sousa lP, Machado 
av, teixeira MM (2010) Platelet-activating factor receptor plays 
a role in lung injury and death caused by Influenza a in mice. 
Plos Pathog 6:e1001171. doi:10.1371/journal.ppat.1001171
 39. saria a, lundberg JM (1983) evans blue fluorescence: quanti-
tative and morphological evaluation of vascular permeability in 
animal tissues. J neurosci Methods 8:41–49
 40. Krege JH, Hodgin JB, Hagaman Jr, smithies O (1995) a non-
invasive computerized tail-cuff system for measuring blood 
pressure in mice. Hypertension 25:1111–1115. doi:10.1161/01.
HYP.25.5.1111
 41. Halstead sB (1989) antibody, macrophages, Dengue virus infec-
tion, shock, and hemorrhage: a pathogenetic cascade. rev Infect 
Dis 11(suppl 4):s830–s839
 42. rajapakse s (2009) Intravenous immunoglobulins in the treat-
ment of dengue illness. trans r soc trop Med Hyg 103:867–
870. doi:10.1016/j.trstmh.2008.12.011
 43. Dimaano eM, saito M, Honda s, Miranda ea, alonzo Mt, 
Dimaano eM, valerio MD, Mapua Ca, Inoue s, Kumaori a, 
Matias r, natividad FF, Oishi K (2007) lack of efficacy of high-
dose intravenous immunoglobulin treatment of severe thrombo-
cytopenia in patients with secondary Dengue virus infection. am 
J trop Med Hyg 77:1135–1138
 44. Kreil tr, eibl MM (1997) Pre- and postexposure protection by 
passive immunoglobulin but no enhancement of infection with a 
flavivirus in a mouse model. J virol 71:2921–2927
 45. guzman Mg, vazquez s (2010) the complexity of antibody-
dependent enhancement of Dengue virus infection. viruses 
2:2649–2662. doi:10.3390/v2122649
 46. Halstead sB (1982) Immune enhancement of viral infection. 
Prog allergy 31:301–364
 47. Diamond Ms, shrestha B, Marri a, Mahan D, engle M (2003) 
B cells and antibody play critical roles in the immediate defense 
250 Med Microbiol Immunol (2014) 203:231–250
1 3
of disseminated infection by West nile encephalitis virus. J virol 
77:2578–2586
 48. Chambers tJ, Droll Da, Walton aH, schwartz J, Wold Ws, 
nickells J (2008) West nile 25a virus infection of B-cell-defi-
cient ((micro)Mt) mice: characterization of neuroinvasiveness 
and pseudoreversion of the viral envelope protein. J gen virol 
89:627–635. doi:10.1099/vir.0.83297-0
 49. Moseman ea, Iannacone M, Bosurgi l, tonti e, Chevrier n, 
Moseman ea, tumanov a, Fu YX, Hacohen n, von andrian UH 
(2012) B cell maintenance of subcapsular sinus macrophages pro-
tects against a fatal viral infection independent of adaptive immu-
nity. Immunity 36:415–426. doi:10.1016/j.immuni.2012.01.013
 50. Kelly-scumpia KM, scumpia PO, Weinstein Js, Delano MJ, 
Cuenca ag, nacionales DC, Wynn Jl, lee PY, Kumagai Y, efron 
Pa, akira s, Wasserfall C, atkinson Ma, Moldawer ll (2011) 
B cells enhance early innate immune responses during bacterial 
sepsis. J exp Med 208:1673–1682. doi:10.1084/jem.20101715
 51. Marchette nJ, Halstead sB, Falkler Wa Jr, stenhouse a, nash D 
(1973) studies on the pathogenesis of dengue infection in mon-
keys. 3. sequential distribution of virus in primary and heterolo-
gous infections. J Infect Dis 128:23–30
 52. Halstead sB (1979) In vivo enhancement of Dengue virus infec-
tion in rhesus monkeys by passively transferred antibody. J Infect 
Dis 140:527–533
 53. goncalvez aP, engle re, st Claire M, Purcell rH, lai CJ 
(2007) Monoclonal antibody-mediated enhancement of Dengue 
virus infection in vitro and in vivo and strategies for prevention. 
Proc natl acad sci Usa 104:9422–9427. doi:10.1073%2Fp
nas.0703498104
 54. Balsitis sJ, Williams Kl, lachica r, Flores D, Kyle Jl, Mehlhop 
e, Johnson s, Diamond Ms, Beatty Pr, Harris e (2010) lethal 
antibody enhancement of dengue disease in mice is prevented 
by Fc modification. Plos Pathog 6:e1000790. doi:10.1371/
journal.ppat.1000790
 55. Zellweger rM, Prestwood tr, shresta s (2010) enhanced infec-
tion of liver sinusoidal endothelial cells in a mouse model of anti-
body-induced severe dengue disease. Cell Host Microbe 7:128–
139. doi:10.1016/j.chom.2010.01.004
 56. suhrbier a, la linn M (2003) suppression of antivi-
ral responses by antibody-dependent enhancement of mac-
rophage infection. trends Immunol 24:165–168. doi:10.1016/
s1471-4906(03)00065-6
 57. Ubol s, Halstead sB (2010) How innate immune mechanisms 
contribute to antibody-enhanced viral infections. Clin vaccine 
Immunol 17:1829–1835. doi:10.1128/CvI.00316-10
 58. Modhiran n, Kalayanarooj s, Ubol s (2010) subversion of 
innate defenses by the interplay between Denv and pre-existing 
enhancing antibodies: tlrs signaling collapse. Plos negl trop 
Dis 4:e924. doi:10.1371/journal.pntd.0000924
 59. Perez aB, sierra B, garcia g, aguirre e, Babel n, Perez aB, 
alvarez M, sanchez l, valdes l, volk HD, guzman Mg (2010) 
tumor necrosis factor-alpha, transforming growth factor-beta1, 
and interleukin-10 gene polymorphisms: implication in protec-
tion or susceptibility to dengue hemorrhagic fever. Hum Immunol 
71:1135–1140. doi:10.1016/j.humimm.2010.08.004
 60. Boonnak K, Dambach KM, Donofrio gC, tassaneetrithep B, 
Marovich Ma (2011) Cell type specificity and host genetic 
polymorphisms influence antibody-dependent enhancement of 
Dengue virus infection. J virol 85:1671–1683. doi:10.1128/
JvI.00220-10
 61. Whitehead ss, Blaney Je, Durbin aP, Murphy Br (2007) Pros-
pects for a Dengue virus vaccine. nat rev Microbiol 5:518–528. 
doi:10.1038/nrmicro1690
 62. Halstead sB (2007) Dengue. lancet 370:1644–1652
 63. nimmerjahn F, ravetch Jv (2008) anti-inflammatory actions of 
intravenous immunoglobulin. annu rev Immunol 26:513–533. 
doi:10.1146/annurev.immunol.26.021607.090232
 64. Ben-nathan D, lustig s, tam g, robinzon s, segal s, rager-
Zisman B (2003) Prophylactic and therapeutic efficacy of human 
intravenous immunoglobulin in treating West nile virus infection 
in mice. J Infect Dis 188:5–12. doi:10.1086/376870
 65. de Castro ra, de Castro Ja, Barez MY, Frias Mv, Dixit J, gener-
eux M (2007) thrombocytopenia associated with dengue hem-
orrhagic fever responds to intravenous administration of anti-D 
(rh(0)-D) immune globulin. am J trop Med Hyg 76:737–742
